Overview
William Gaede successfully argued for Ambry Genetics before the Federal Circuit, which invalidated claims on three gene testing patents held by competitor Myriad Genetics. Following a key Supreme Court decision rejecting Myriad’s patents, Ambry Genetics began marketing its own, less expensive medical kit for determining susceptibility to breast or ovarian cancer, and Myriad and its research partners sought an injunction to halt the sale.
